VARON Launches Hot Summer Sale to Help Customers Stay Cool and Oxygenated
With the Summer Sale, VARON aims to ensure that individuals with respiratory needs can stay active and well-supported—even during peak heat or vacation plans. The following limited-time offers are now available as part of the VARON Summer Sale:
VARON Summer Sale Highlights
18% Off Sitewide
Up to 40% Off select oxygen concentrators and featured bundles
Free Shipping on orders over $49
No coupon needed – discounts applied automatically at checkout
The Summer Sale is only available for a limited time.
Shop VARON's Summer Sale now
Travel Light, Breathe Freely: Portable Oxygen Solutions for Summer Adventures
Whether you're planning a weekend road trip or a long-awaited vacation, staying mobile shouldn't mean compromising your oxygen. VARON's portable oxygen concentrators are compact, quiet, and designed for on-the-go freedom—with car adapters, long-lasting rechargeable batteries, and travel-ready accessories. These devices empower users to travel with confidence and comfort.
Among VARON's small portable oxygen concentrator, the new VP-8G has quickly become a customer favorite since its launch—thanks to its ultra-lightweight design, dependable oxygen delivery, and travel-friendly features. With summer in full swing, many users are finding it the perfect choice for staying active and comfortable on the go.
'Lightweight, quiet, and easy to carry—I finally feel free to go anywhere I want!' — Michelle R., Florida
'The VP-8G is a game-changer for my daily life. The battery lasts longer than expected, and I love the compact design.' — George T., California
See our best-selling portable oxygen concentrators built for travel.
Powerful Oxygen Support for Everyday Home Use
For those spending more time at home, VARON's oxygen concentrators for home provide continuous oxygen, quiet operation, and sleek, compact designs—eliminating the hassle of bulky tanks. These devices combine high performance with everyday convenience, including user-friendly interfaces, a full set of accessories, remote controls, and more.
Discover VARON's Oxygen Concentrators for Home Now.
Stay Safe with Smart Oxygen Use in Summer Heat
High temperatures can pose challenges for oxygen machine users. To ensure optimal performance and safety, VARON shares these important summer tips:
Use devices in cool, well-ventilated areas, preferably with air conditioning. If used outdoors in high heat, give the machine a few minutes to cool down every two hours.
Never leave oxygen concentrators or batteries inside vehicles parked in the sun, where temperatures can rise rapidly.
Always carry spare, fully charged batteries when on the go.
Clean air filters regularly to maintain efficiency and airflow.
Store equipment away from direct sunlight and high humidity.
Enjoy Every Breath This Summer with VARON
Whether you're relaxing at home or heading out for your next adventure, VARON helps you stay cool, stay active, and stay oxygenated all season long. Experience the reliability, portability, and performance of VARON oxygen concentrators—backed by unbeatable summer deals.
About VARON
VARON is a trusted global brand offering advanced oxygen concentrators for both home and travel use. Dedicated to supporting respiratory wellness, VARON empowers users with innovative, easy-to-use devices that promote independence, mobility, and peace of mind.
Media Contact:VARON Oxygen SolutionsEmail: official@varoninc.comWebsite: www.varoninc.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
29 minutes ago
- Malaysian Reserve
Elixir MD Launches Australia & New Zealand Subsidiary in Exclusive Partnership with High Tech Medical Pty. Ltd.
IRVINE, Calif. and QUEENSLAND, Australia, Aug. 1, 2025 /PRNewswire/ — ELIXIR MD, Inc., a pioneer in advanced medical technology and proprietary treatment protocols for plastic surgery, today announced the formation of its wholly owned subsidiary in Australia and New Zealand, alongside an exclusive partnership with High Tech Medical Pty Ltd. to launch the ELIXIR MD™ device across the region. Ewan Mohammed, CEO of ELIXIR MD, Inc., stated:'We're proud to join forces with High Tech Medical—Australia and New Zealand's leading medical technology partner—to bring the ELIXIR MD™ device to facial surgery patients across one of the world's fastest-growing cosmetic markets. With more than 25 years of proven commitment to clinical excellence, High Tech Medical brings deep market insight and trusted relationships throughout the aesthetic medical community. Their long-standing success in introducing advanced technologies to Australians and New Zealanders makes them the ideal partner for ELIXIR MD, Inc.' Matt Moncrieff, Managing Director of High-Tech Medical Pty Ltd., added:'High Tech Medical is proud to work exclusively with ELIXIR MD, Inc., Ewan and the entire team have demonstrated a clear commitment to innovation and to reshaping the perioperative care model in plastic surgery. The ELIXIR MD™ device and its proprietary treatment protocols represent a new gold standard in post-surgical recovery by significantly reducing patient downtime and improving outcomes.' Australia and New Zealand: A Rising Market for Surgical Innovation Australian cosmetic surgery market reached approximately $1.8B in 2024, with expected growth to $3.9B by 2033, reflecting a CAGR of ~9.3% (IMARC Group, Rentech Digital). Facial cosmetic surgery—the category where ELIXIR MD™ is uniquely focused—is the fastest-growing segment of the cosmetic surgery market in Australia, with a projected CAGR of approximately 14.1% through 2030 (Grand View Research). Demand for face and eyelid surgeries (e.g. blepharoplasty, facelifts) is rising sharply in Australia and New Zealand, in key part driven by post-weight loss volume depletion and rejuvenation surgery (Daily Telegraph). About High Tech Medical Pty in 1999, High Tech Medical is one of the most respected providers of specialist aesthetic medical devices across Australia and New Zealand. With over two decades of leadership, the company has introduced breakthrough technologies that support minimally invasive treatments, reduce patient risk and downtime, and improve clinical outcomes. High Tech Medical is known for its consultative approach—helping practitioners select and integrate complex, high-performance systems into their practices with confidence. About ELIXIR MD, in Irvine, California, ELIXIR MD, Inc. is a medical technology company redefining recovery in plastic surgery through non-invasive, perioperative innovations. Now operating in 18 markets—including a wholly owned subsidiary in Australia and New Zealand—our FDA-cleared ELIXIR MD™ technology is built to support faster healing and better outcomes for surgeons and their patients worldwide.
Malaysian Reserve
10 hours ago
- Malaysian Reserve
ASPIRE for Lung Cancer launches the APAC Lung Cancer Policy Consensus as a regional call to action for improved lung cancer care
SINGAPORE, Aug. 1, 2025 /PRNewswire/ — On 31st July 2025, a unified consensus document for improving lung cancer care in the Asia-Pacific (APAC) region was officially launched in Singapore, marking a pivotal moment in the regional fight against lung cancer. This represents the first comprehensive consensus for the region, an evidence-based agreement between stakeholders across the healthcare ecosystem that outlines shared priorities, strategies, and recommendations to elevate the standard of lung cancer care across diverse health systems. Held on the eve of World Lung Cancer Day, the initiative involved over 43 contributors, including clinicians, academics, patient advocates, and health organisations across 14 APAC health systems. Launch Highlights and Key Voices The APAC Lung Cancer Policy Consensus was launched with keynote contributions from: Dr Mary Bussell (TriMar Strategies), who delivered an overview of the global lung cancer consensus and its relevance to regional efforts Mr Yannick Romero (Union for International Cancer Control – UICC), who contextualised the APAC consensus within the broader global lung health resolution, emphasising policy alignment and strategic integration Ms Helena Wilcox (The Lung Cancer Policy Network – LCPN), who highlighted how the APAC framework enables regional advancement in care and partnership building Mr Francis Goh (Lung Cancer Education and Advocacy for Patients – LEAP), Singapore) stressed the pivotal role of patient voices in shaping lung cancer policy and health system transformation A/Prof Herbert Loong (Asia Pacific Coalition against Lung Cancer – APCLC) and Asst Prof Yeon Wook Kim (SNU Bundang Hospital), who provided an in-depth presentation on the consensus development process, five key pillars, and concrete calls to action Lung cancer remains the leading cause of cancer-related deaths in the APAC region, and accounts for nearly 60% of global cases. With regional incidence projected to exceed 1.8 million by 2040, the need for a cohesive, regional strategy to combat the disease has never been more urgent. Furthermore, survival rates in the APAC region often lag behind global benchmarks, with five-year survival rates frequently below 20%. This fragmented landscape highlights the critical need for a coordinated approach, one that addresses the unique epidemiological, environmental, and healthcare challenges within the region. The APAC Lung Cancer Policy Consensus is the result of an extensive collaborative process involving two expert working sessions, one patient workshop and a final expert voting session, with input from patients, clinicians and academic leaders across the region. The consensus lays out a unified policy framework anchored in five core principles, all aimed at driving sustainable, equitable improvements in lung cancer prevention, detection, treatment, and stigma reduction across the region. Importantly, the APAC Consensus aligns closely with the Global Lung Cancer Consensus, which was first ratified at the 9th International Lung Cancer Network in 2023. By endorsing this global statement, the APAC region reaffirms its commitment to improving lung cancer outcomes. The Five Global Principles Anchoring the APAC Lung Cancer Policy Consensus: Improve and Expand Prevention Strengthen tobacco control, public education, and environmental risk research to prevent lung cancer across all exposure types Expand screening and diagnostic access through inclusive guidelines and innovative technologies to enable timely lung cancer detection Promote timely, affordable access to modern and personalised lung cancer treatments across diverse healthcare settings Foster cross-sectoral collaboration and advocacy to drive investment and policy reform in lung cancer care Address stigma through education and empowerment to support early diagnosis, treatment adherence, and community acceptance A Region-Specific Approach to Lung Cancer Care The APAC Lung Cancer Policy Consensus is not just a regional adaptation of global recommendations; it is a comprehensive response to the distinct challenges faced by the APAC region. Unlike Western health systems that primarily focus on smoking-related lung cancer, the APAC region must contend with a higher prevalence of lung cancer in never-smokers due to factors such as environmental pollutants, and genetic predispositions. Moreover, the region's healthcare systems are highly heterogeneous, ranging from well-resourced settings with cutting-edge cancer care to lower-resource environments building on basic cancer services. Given these disparities, a one-size-fits-all approach would be ineffective. The APAC Lung Cancer Policy Consensus presents a regionally tailored action plan that offers specific strategies and targets to improve lung cancer care and outcomes, ensuring that every health system in the region, regardless of its capacity, can make progress toward the shared goals. 'We call on policymakers, healthcare leaders, and stakeholders across the APAC region to urgently prioritise and implement policies that improve lung cancer outcomes. While the specific solutions will vary across health systems, this consensus provides a shared foundation to guide national efforts. By acting now and adapting these recommendations to local contexts, we can foster a future where healthcare systems of all sizes work together to overcome regional challenges.' said Judy Li, Consortium Manager at ASPIRE for Lung Cancer. Looking Ahead The launch of the APAC Lung Cancer Policy Consensus marks the start of a sustained regional effort to transform lung cancer care in the Asia-Pacific region. Over the coming months, ASPIRE for Lung Cancer and its partners will continue to engage with policymakers, healthcare leaders, and patient advocacy groups to ensure that the consensus principles are translated into concrete action, with measurable outcomes. Through this regional collaboration, APAC aims to drive meaningful change that will improve survival rates and quality of life for lung cancer patients across the region. For more details about the APAC Lung Cancer Policy Consensus or to learn how you can get involved in advancing lung cancer care in your region, visit About ASPIRE for Lung Cancer ASPIRE (Asia Pacific Policy Review and Engagement) for Lung Cancer is a collaborative multilateral effort focused on improving lung cancer outcomes in the Asia-Pacific region through policy reforms. We advocate for prioritising lung cancer in government action plans, aiming to drive transformative changes that enhance patient access and care. We believe in the influence of collaboration and collective action to drive positive change. We therefore work with governments, agencies, NGOs and patient groups, bringing together multi-disciplinary experts to improve health outcomes for lung cancer patients in the APAC region. CONTACT: ASPIRE for Lung Cancer,
The Star
18 hours ago
- The Star
Address manpower shortage in health sector, govt urged
PETALING JAYA: The RM40bil allocation under the 13th Malaysia Plan (13MP) comes as a relief to the healthcare sector. But stakeholders say a solution to manpower issues plaguing the public healthcare sector must be resolved. They lauded the expansion of pro-health taxes to include tobacco, vape and alcohol, as this would reduce the use of such substances while at the same time increase the government's coffers. Malaysian Medical Association (MMA) president Dr Kalwinder Singh Khaira welcomed the RM40bil allocation for the health sector under the 13MP and the government's commitment to strengthen the public health system. However, he said addressing the critical shortage of healthcare workers must be prioritised, as this continues to be one of the biggest challenges facing public healthcare facilities. 'We welcome the 13MP initiatives and plans for a national framework for development in the health sector to address human resource needs. 'We hope that these efforts will encompass all healthcare professions in the healthcare ecosystem,' he said. 'We note the government's plans to upgrade over 1,700 dilapidated public health clinics and build more healthcare facilities across the country. 'These are timely and necessary steps, but there must be clear timelines for the implementation of each initiative to ensure accountability. 'Planning of human resources must also follow for any new facilities being planned. 'MMA strongly supports the move to strengthen digitalisation, including improvements in health record management and the use of artificial intelligence (AI) to enhance healthcare delivery. 'These efforts are crucial to improving continuity of care and enabling data-driven health planning,' he added. Dr Kalwinder said the expansion of pro-health taxes to include tobacco, vape and alcohol is a step in the right direction in curbing the rise in non-communicable diseases (NCDs). 'However, MMA maintains its firm position that a total ban on vaping and vaping products is necessary to protect public health, especially the health of our youth,' he said. Former Health Ministry director Datuk Zainal Ariffin Omar said the RM40bil allocation for health and the upgrade works for 1,776 dilapidated clinics will improve healthcare accessibility, especially in rural and underserved areas, therefore reducing overcrowding in major hospitals. However, he said the government must ensure the funds are used efficiently, avoid delays and maintain quality amid expansion. 'The health proposals under 13MP are ambitious and yet necessary. It addresses infrastructure gaps, preventive care, and digital transformation. However, execution efficiency, equitable access, tech adoption and adequate staff will determine its success. 'The pro-health taxes align with global best practices but require complementary policies to avoid burdening vulnerable groups,' he said. The higher taxes, he said, discourage unhealthy consumption and generate revenue for the government's coffers, adding that the success depends on strict enforcement and public awareness campaigns. He said this must also be coupled with subsidies for healthy alternatives. Dr Zainal said while the use of AI can improve diagnostics, predict outbreaks and personalise treatment, it comes with some barriers, which include high costs, the need for trained personnel, and ethical concerns. He said the RM40bil allocation over the period of five years is reasonable for the underfunded healthcare sector, considering that this is on top of the allocation under the annual budget. Prof Dr Sharifa Ezat Wan Puteh, dean of Universiti Kebangsaan Malaysia's School of Liberal Sciences Public Health Medicine Specialists, said while the initiatives are good, pertinent issues such as low wages for doctors were not addressed. This, she said, is the cause of doctors leaving the service. 'Building and improving facilities is good, but what if we do not have the manpower for them?' she said. 'I have some reservations on tobacco and vape taxes. While increasing taxes will lead to reduced demand, data has shown that the black market makes up for almost 50% to 60%. This means that most of these products are not taxed. 'Hence, illicit tobacco will be sold cheaper to the consumers. So, increasing the tax on legal products will push smokers to continue buying black market products instead,' she said. Consumers Association of Penang education officer N.V. Subbarow said the pro-health taxes should be branded as 'cancer tax'.
